Live Breaking News & Updates on Ustainable Long Term Competitive

Hikal hit an upper circuit of 10% at Rs 313.65 after the company said it signed a 10-year multi product deal with a leading global pharmaceutical innovator company.The contract entails the development and supply of a portfolio of niche APIs over a period of 10 years. The development will start this year and commercial supplies will commence post successful development and plant commercialisation estimated to be in FY 2024 onwards. With this deal, Hikal is entering into a niche area of chemistry and products thereby bolstering its animal health vertical. Hikal and its customer will be jointly investing at its Panoli, Gujarat site to setup a multipurpose manufacturing asset for manufacturing of these APIs. ....

Sameer Hiremath , Capital Market , Pharmaceutical Industry , Harmaceuticals Nec , Manufacturing Facility , Ultipurpose Manufacturing Asset , Chemicals Industry , Innovator Pharmaceutical , Chief Executive Officer Ceo , Ustainable Long Term Competitive , மூலதனம் சந்தை , மருந்து தொழில் ,